Related Experiment Videos
Molecular modelling of epitope presentation using membrane protein OmpC
S Sujatha1, A Arockiasamy, S Krishnaswamy
1Bioinformatics Centre, School of Biotechnology, Madurai Kamaraj University, India.
Indian Journal of Biochemistry & Biophysics
|March 12, 2002
Summary
Computer models of chimeric Salmonella typhi OmpC proteins show that a rotavirus epitope is more accessible on the fourth loop than the sixth. This finding aligns with experimental results on epitope immunogenicity.
Area of Science:
- Structural biology
- Computational modeling
- Vaccine design
Background:
- Salmonella typhi outer membrane protein C (OmpC) is a potential vaccine carrier.
- Incorporating foreign epitopes into OmpC can create chimeric vaccines.
- Understanding epitope presentation is crucial for vaccine efficacy.
Purpose of the Study:
- To construct and analyze 3D models of chimeric S. typhi OmpC proteins.
- To evaluate the surface accessibility of a rotavirus VP4 epitope inserted into different OmpC loops.
- To correlate model predictions with experimental immunogenicity data.
Main Methods:
- Computer-aided homology modeling using the S. typhi OmpC structure as a template.
- Energy minimization of monomers and optimization of trimeric structures.
- Surface accessibility calculations to predict epitope exposure.
Main Results:
- 3D models of chimeric S. typhi OmpC with rotavirus VP4 epitopes on the fourth and sixth loops were successfully constructed.
- Surface accessibility calculations indicated greater epitope exposure on the fourth loop compared to the sixth loop.
- These computational findings are consistent with experimental data showing higher immunogenicity for the fourth loop insertion.
Conclusions:
- The fourth loop of S. typhi OmpC is a more favorable site for presenting the rotavirus VP4 epitope for enhanced immunogenicity.
- Computational modeling provides valuable insights into epitope presentation and can guide chimeric vaccine development.
- This study supports the use of S. typhi OmpC as a scaffold for developing multivalent vaccines.